Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Type 2 Diabetes (Pakistan)
NCT05249881Phase 1Unknown
- Sponsor
- Aga Khan University
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Aga Khan University. Primary endpoint: Change in glycemic Index in Diabetes mellitus type-2 Patients at 3 months. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05249881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249881.